Supplemental Table S1. Efficacy of JAK1 inhibitors and dupilumab.

EASI, Eczema Area and Severity Index; EASI-50/75: improvement of at least 50%/75% in the EASI score compared to baseline; IGA, Investigator's Global Assessment; IQR, interquartile range; JAK, Janus kinase 1; SCORAD, SCORing Atopic Dermatitis; WP-NRS, Weekly Peak Pruritus Numeric Rating Scale. Continuous variables are presented as median [IQR], and categorical variables are presented as counts (percentages). Data missing: 1 n=14; 2 n=7.